Is EP Biocomposites overvalued or undervalued?

As of 7 October 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive, indicating a shift in market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 19.59, an EV to EBITDA of 12.10, and a ROCE of 13.97%.
In comparison to peers, EP Biocomposites has a lower PE ratio than Altius Telecom, which stands at 54.74, but is higher than the average for its industry. The company’s PEG ratio is notably at 0.00, suggesting no growth expectations are priced in, which is unusual. Recent stock performance has been poor, with a year-to-date return of -29.82%, contrasting sharply with a Sensex return of 4.85%, further reinforcing the view that the stock is overvalued.